Congenital anomalies and in utero antiretroviral exposure in human immunodeficiency virus-exposed uninfected infants

JAMA Pediatrics

Volumn 169, Issue 1, 2015, Pages 48-55

  Williams, Paige L ^a,b   Crain, Marilyn J ^c   Yildirim, Cenk ^a   Hazra, Rohan ^d   Van Dyke, Russell B ^e   Rich, Kenneth ^f   Read, Jennifer S ^g   Stuard, Emma ^h   Rathore, Mobeen ⁱ   Mendez, Hermann A ^j   Watts, D Heather ^k  

^a CENTER FOR BIOSTATISTICS IN AIDS RESEARCH   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^e TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^g NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^h BRONX LEBANON HOSPITAL CENTER   (United States)

ⁱ UNIVERSITY OF FLORIDA   (United States)

^j SUNY DOWNSTATE MEDICAL CENTER   (United States)

^k U S DEPARTMENT OF STATE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIDEPRESSANT AGENT; ANTIRETROVIRUS AGENT; ATAZANAVIR; DARUNAVIR; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; FOLIC ACID ANTAGONIST; FOSAMPRENAVIR; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; SEROTONIN UPTAKE INHIBITOR; STAVUDINE; TENOFOVIR; TENOFOVIR DISOPROXIL; ZIDOVUDINE;

ADULT; ARTICLE; BIRTH; CARDIOVASCULAR MALFORMATION; CHILD; CLINICAL EVALUATION; COHORT ANALYSIS; CONGENITAL MALFORMATION; CONTROLLED STUDY; DEMOGRAPHY; DISEASE REGISTRY; DOUBLE BLIND PROCEDURE; DRUG SAFETY; FEMALE; FIRST TRIMESTER PREGNANCY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; LOGISTIC REGRESSION ANALYSIS; LOW BIRTH WEIGHT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; PHYSICAL EXAMINATION; PREGNANT WOMAN; PREMATURE LABOR; PRENATAL DRUG EXPOSURE; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SKIN MALFORMATION; UNITED STATES; ABNORMALITIES, DRUG-INDUCED; CHEMICALLY INDUCED; GEORGIA; HIV INFECTIONS; NEWBORN; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PRENATAL EXPOSURE; PREVENTION AND CONTROL; TRANSMISSION; TREATMENT OUTCOME; VERTICAL TRANSMISSION;

ABNORMALITIES, DRUG-INDUCED; ANTI-RETROVIRAL AGENTS; FEMALE; GEORGIA; HIV INFECTIONS; HUMANS; INFANT, NEWBORN; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PREGNANCY TRIMESTER, FIRST; PRENATAL EXPOSURE DELAYED EFFECTS; PREVALENCE; PROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME;

EID: 84930733315     PISSN: 21686203     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamapediatrics.2014.1889     Document Type: Article

References (32)

1. Townsend CL, Cortina-Borja M, Peckham CS, de Ruiter A, Lyall H, Tookey PA. Lowrates of mother-to-child transmission of HIV following effective pregnancy interventions in the United Kingdom and Ireland, 2000-2006. AIDS. 2008;22(8):973-981.
2. Watts DH. Treating HIV during pregnancy: an update on safety issues. Drug Saf. 2006;29(6):467-490.
3. Patel D, Thorne C, Fiore S, Newell ML; European Collaborative Study. Does highly active antiretroviral therapy increase the risk of congenital anomalies in HIV-infected women? J Acquir Immune Defic Syndr. 2005;40(1):116-118.
4. Townsend CL, Willey BA, Cortina-Borja M, Peckham CS, Tookey PA. Antiretroviral therapy and congenital abnormalities in infants born to HIV-infected women in the UK and Ireland, 1990-2007. AIDS. 2009;23(4):519-524.
5. Antiretroviral Pregnancy Registry. Antiretroviral Pregnancy Registry International Interim Report for 1 January 1989 through 31 July 2013. 2013. http://www.apregistry.com/forms/interim-report.pdf. Accessed September 17, 2014.
6. Watts DH, Li D, Handelsman E, et al. Assessment of birth defects according to maternal therapy among infants in the Women and Infants Transmission Study. J Acquir Immune Defic Syndr. 2007;44(3):299-305.
7. Watts DH, Huang S, Culnane M, et al. Birth defects among a cohort of infants born to HIV-infected women on antiretroviral medication. J Perinat Med. 2011;39(2):163-170.
8. Covington DL, Conner SD, Doi PA, Swinson J, Daniels EM. Risk of birth defects associated with nelfinavir exposure during pregnancy. Obstet Gynecol. 2004;103(6):1181-1189.
9. Roberts SS, Martinez M, Covington DL, Rode RA, Pasley MV,Woodward WC. Lopinavir/ritonavir in pregnancy. J Acquir Immune Defic Syndr. 2009;51(4):456-461.
10. Floridia M, Mastroiacovo P, Tamburrini E, et al Italian Group on Surveillance on Antiretroviral Treatment in Pregnancy. Birth defects in a national cohort of pregnant women with HIV infection in Italy, 2001-2011. BJOG. 2013;120(12):1466-1475.
11. Phiri K, Hernandez-Diaz S, Dugan KB, et al. First trimester exposure to antiretroviral therapy and risk of birth defects. Pediatr Infect Dis J. 2014;33(7):741-746.
12. Brogly SB, Abzug MJ, Watts DH, et al. Birth defects among children born to human immunodeficiency virus-infected women: Pediatric AIDS Clinical Trials protocols 219 and 219C. Pediatr Infect Dis J. 2010;29(8):721-727.
13. Knapp KM, Brogly SB, Muenz DG, et al. Prevalence of congenital anomalies in infants with in utero exposure to antiretrovirals. Pediatr Infect Dis J. 2012;31(2):164-170.
14. De Santis M, Carducci B, De Santis L, Cavaliere AF, Straface G. Periconceptional exposure to efavirenz and neural tube defects. Arch Intern Med. 2002;162(3):355.
15. Saitoh A, Hull AD, Franklin P, Spector SA. Myelomeningocele in an infant with intrauterine exposure to efavirenz. J Perinatol. 2005;25(8):555-556.
16. Griner R, Williams PL, Read JS, et al Pediatric HIV/AIDS Cohort Study. In utero and postnatal exposure to antiretrovirals among HIV-exposed but uninfected children in the United States. AIDS Patient Care STDS. 2011;25(7):385-394.
17. Phiri K, Fischer MA, Mogun H, et al. Trends in antiretroviral drug use during pregnancy among HIV-infected women on Medicaid: 2000-2007. AIDS Patient Care STDS. 2014;28(2):56-65.
18. Floridia M, Ravizza M, Guaraldi G, Pinnetti C, Martinelli P, Tamburrini E; Italian Group on Surveillance on Antiretroviral Treatment in Pregnancy. Use of specific antiretroviral regimens among HIV-infected women in Italy at time of conception: 2001-2011. AIDS Patient Care STDS. 2012;26(8):439-443.
19. Williams PL, Seage GR III, Van Dyke RB, et al Pediatric HIV/AIDS Cohort Study. A trigger-based design for evaluating the safety of in utero antiretroviral exposure in uninfected children of HIV-infected mothers. Am J Epidemiol. 2012;175(9):950-961.
20. Hernán MA, Hernández-Díaz S,Werler MM, Mitchell AA. Causal knowledge as a prerequisite for confounding evaluation: an application to birth defects epidemiology. Am J Epidemiol. 2002;155(2):176-184.
21. Wilcox AJ, Weinberg CR, Basso O. On the pitfalls of adjusting for gestational age at birth. Am J Epidemiol. 2011;174(9):1062-1068.
22. Louik C, Lin AE,Werler MM, Hernández-Díaz S, Mitchell AA. First-trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects. N Engl J Med. 2007;356(26):2675-2683.
23. Huybrechts KF, Palmsten K, Avorn J, et al. Antidepressant use in pregnancy and the risk of cardiac defects. N Engl J Med. 2014;370(25):2397-2407.
24. de Jonge L, Zetstra-van derWoude PA, Bos HJ, de Jong-van den Berg LT, Bakker MK. Identifying associations between maternal medication use and birth defects using a case-population approach: an exploratory study on signal detection. Drug Saf. 2013;36(11):1069-1078.
25. van Gelder MM, de Jong-van den Berg LT, Roeleveld N. Drugs associated with teratogenic mechanisms. Part II: a literature review of the evidence on human risks. Hum Reprod. 2014;29(1):168-183.
26. Tassiopoulos K, Read JS, Brogly S, et al. Substance use in HIV-infected women during pregnancy: self-report versus meconium analysis. AIDS Behav. 2010;14(6):1269-1278.
27. Joao EC, Calvet GA, Krauss MR, et al NISDI Perinatal Study Group. Maternal antiretroviral use during pregnancy and infant congenital anomalies: the NISDI Perinatal Study. J Acquir Immune Defic Syndr. 2010;53(2):176-185.
28. Cambra K, Ibañez B, Urzelai D, et al. Trends in the prevalences of congenital anomalies and age at motherhood in a southern European region: a population-based study. BMJ Open. 2014;4(3): e004244. doi:10.1136/bmjopen-2013-004244.
29. Richard-Tremblay AA, Sheehy O, Bérard A. Annual trends in use of periconceptional folic acid and birth prevalence of major congenital malformations. Curr Drug Saf. 2013;8(3):153-161.
30. Ford N, Calmy A, Mofenson L. Safety of efavirenz in the first trimester of pregnancy: an updated systematic review andmeta-analysis. AIDS. 2011;25(18):2301-2304.
31. Agopian AJ, Langlois PH, Ramakrishnan A, Canfield MA. Epidemiologic features of male genital malformations and subtypes in Texas. Am J Med Genet A. 2014;164A(4):943-949.
32. Ishikawa N, Shimbo T, Miyano S, et al. Health outcomes and cost impact of the new WHO 2013 guidelines on prevention of mother-to-child transmission of HIV in Zambia. PLoS One. 2014;9(3):e90991. doi:10.1371/journal.pone.0090991.